Stopped the Medication.
The Damage Didn't Stop.
Post-SSRI Sexual Dysfunction is a recognized medical condition — genital numbness, inability to orgasm, loss of libido, and emotional blunting that persist for months or years after discontinuing an antidepressant. The FDA and European regulators have mandated PSSD warnings. Manufacturers who withheld this risk face active lawsuits — and attorneys handling PSSD claims are reviewing cases nationwide.
Litigation Status
Regulators Confirmed It.
Manufacturers Hid It.
PSSD was reported by patients for years before manufacturers were forced to acknowledge it. The FDA required updated SSRI labeling. The EMA followed. Attorneys are now pursuing the manufacturers who kept patients in the dark while the evidence accumulated.
The FDA required manufacturers to update prescribing information for SSRIs and SNRIs to disclose the risk of persistent sexual dysfunction after stopping the drug. This regulatory action is central to current PSSD litigation — it establishes the harm was known and the prior labeling was inadequate.
PSSD lawsuits are active and expanding. Claims allege failure to warn against manufacturers including Pfizer, GlaxoSmithKline, Eli Lilly, and Forest Laboratories — whose SSRIs and SNRIs were prescribed to millions of patients without adequate disclosure of the risk of permanent sexual and emotional dysfunction.
Attorneys in this network handle PSSD lawsuits on pure contingency. No retainer. No hourly billing. No upfront fees. If no compensation is recovered on your behalf, you owe nothing — period.
"Patients reported it for years. The label said nothing. The courts are listening now."
Injuries & Legal Theories
What PSSD Lawsuits
Are Built On
PSSD lawsuits rest on a documented failure to warn — manufacturers had access to patient reports, adverse event data, and scientific literature linking SSRIs and SNRIs to post-discontinuation sexual dysfunction, and concealed or minimized this risk in product labeling. A connected attorney will assess which drug and theory applies to your situation at no cost.
Genital Numbness & Anesthesia — Persistent Sensory Dysfunction
Persistent genital anesthesia — total or partial loss of genital sensation that continues after stopping an SSRI or SNRI — is one of the hallmark symptoms of PSSD and one of the most frequently reported in adverse event databases worldwide. Claims allege manufacturers had access to these reports and failed to disclose the risk to patients or physicians.
Anorgasmia & Inability to Orgasm After Stopping Antidepressants
Anorgasmia — the inability to reach orgasm despite adequate stimulation — persisting beyond the point of antidepressant discontinuation is a documented PSSD symptom. Manufacturers were aware from clinical trial data and post-market surveillance that sexual dysfunction could outlast treatment, and omitted this from informed consent materials and prescribing labeling.
Emotional Blunting & Anhedonia — The Affective Dimension of PSSD
Beyond physical sexual dysfunction, PSSD frequently involves profound emotional blunting — an inability to feel pleasure, excitement, or emotional connection — that persists indefinitely after the drug is stopped. This affective component has been described by patients as more debilitating than the sexual symptoms alone, and was not disclosed in manufacturer labeling.
Failure to Warn — FDA Label History & Regulatory Concealment
The bedrock of PSSD lawsuits is a failure-to-warn theory: manufacturers received years of adverse event reports describing persistent post-discontinuation sexual dysfunction, had a duty to update product labeling, and failed to do so until compelled by regulatory action. The gap between knowledge and disclosure is the center of legal liability in these cases.
SNRI Claims — Effexor, Cymbalta & Venlafaxine PSSD Lawsuits
Post-discontinuation sexual dysfunction is not limited to SSRIs. SNRIs including Effexor (venlafaxine) and Cymbalta (duloxetine) have been associated with PSSD symptoms in medical literature and adverse event reports. Lawsuits against Pfizer and Eli Lilly for SNRI-related PSSD are being evaluated on the same failure-to-warn theories as SSRI claims.
Loss of Libido — Persistent Low or Absent Sexual Desire After SSRIs
While reduced libido is commonly disclosed as an on-treatment side effect, the persistence of this loss after stopping an antidepressant — in some cases indefinitely — was not adequately communicated to patients. PSSD lawsuits allege that the distinction between transient and persistent libido loss was known to manufacturers and deliberately omitted from patient-facing materials.
Eligibility
Signs Your Situation
May Support a Claim
The core question is whether you experienced persistent sexual, emotional, or sensory dysfunction that began during or after an SSRI or SNRI prescription and has continued beyond the drug's discontinuation. A connected attorney makes the final determination at no cost.
Sexual dysfunction persisted for months or years after you stopped your antidepressant
PSSD is defined by persistence — the symptoms that distinguish it from ordinary on-treatment side effects are that they do not resolve after stopping the drug. If your sexual dysfunction has lasted three months or more post-discontinuation, that timeline may support a PSSD lawsuit claim.
You experience genital numbness or reduced sensation with no other identified cause
Persistent genital anesthesia — especially when it began during SSRI or SNRI treatment and has continued after stopping — is a qualifying PSSD symptom. A connected attorney can assess whether your sensory symptoms align with recognized PSSD criteria.
You took Zoloft, Paxil, Prozac, Lexapro, Effexor, Cymbalta, or another SSRI/SNRI
PSSD lawsuits have been brought in connection with all major SSRIs and SNRIs. The specific drug matters for identifying the manufacturer and the applicable warning history. A connected attorney can evaluate whether the antidepressant you took is a viable basis for a PSSD claim.
You were not warned that PSSD could be permanent before starting or stopping your medication
The failure-to-warn theory at the center of PSSD litigation depends on what your prescribing information and physician disclosed. If you were told sexual side effects would resolve after stopping the drug — or if the topic was never raised — that is directly relevant to your claim.
You experience emotional blunting, anhedonia, or inability to feel pleasure since stopping your SSRI
The affective dimension of PSSD — emotional flatness, inability to experience excitement or connection, persistent anhedonia — is recognized in the scientific and regulatory literature. Emotional blunting that persists after SSRI discontinuation may qualify as part of a PSSD claim alongside physical sexual symptoms.
Your PSSD symptoms began or were identified within the applicable statute of limitations window
Statutes of limitation vary by state and the discovery rule may apply — meaning the clock runs from when you first connected your symptoms to your prior SSRI use. A connected attorney can identify the exact deadline in your state at no cost.
How It Works
No Upfront Costs.
Handled Start to Finish.
Attorneys in this network manage the complete PSSD lawsuit process from evaluation through resolution. Your role is sharing your history — everything else is handled.
Free Confidential Evaluation
A connected attorney reviews your antidepressant history and the PSSD symptoms you've experienced. You'll quickly learn whether your situation supports a viable claim — no cost, no obligation.
Medical & Prescription Evidence
Prescription records, pharmacy history, medical notes, and expert evaluation are gathered to document both your SSRI or SNRI use and the persistent dysfunction that followed — the evidentiary core of a PSSD claim.
Filing Against the Manufacturer
Your PSSD lawsuit is filed against the appropriate manufacturer — Pfizer, GlaxoSmithKline, Eli Lilly, Forest Laboratories, or others — under product liability and failure-to-warn theories supported by FDA regulatory history.
Settlement or Resolution
Attorneys in this network collect a contingency fee only from your recovery. There is nothing to pay at any point during the process — no retainer, no hourly rate, no upfront fees of any kind.
From Those Who Filed
Their Words
"I stopped Lexapro almost two years ago. The numbness never went away. My doctor kept telling me it would resolve on its own. When I learned PSSD was in the FDA label, I was furious — nobody told me."
"I took Effexor for three years for anxiety. After I tapered off, I couldn't feel anything — emotionally or physically. It destroyed my relationship. I had no idea this had a name, let alone a lawsuit."
"Paxil gave me my life back for the first time in years. But when I stopped it, something essential didn't come back with me. The free evaluation with a connected attorney took about 15 minutes. I wish I'd done it sooner."
Common Questions
What You Need to Know
Yes. PSSD lawsuits are active and being pursued against manufacturers of major SSRIs and SNRIs. Claims allege that Pfizer, GlaxoSmithKline, Eli Lilly, and others were aware that their antidepressants could cause permanent sexual and emotional dysfunction after stopping, and failed to warn patients before regulatory agencies forced their hand. Submit your information for a free evaluation to find out if your situation qualifies.
PSSD is a recognized medical condition in which sexual dysfunction — genital numbness, anorgasmia, loss of libido, diminished arousal — persists for months or years after stopping an antidepressant. The FDA and European Medicines Agency have both required manufacturers to disclose this risk. Whether PSSD is permanent varies; for many patients symptoms have shown no spontaneous resolution. A connected attorney can evaluate your specific situation at no cost.
Potentially yes. If you stopped Zoloft, Paxil, or another SSRI and subsequently experienced persistent genital numbness, anorgasmia, loss of libido, or emotional blunting lasting months or longer, you may have a viable PSSD claim under failure-to-warn product liability theories. The core allegation is that manufacturers knew about this risk and withheld it from patients and physicians. A connected attorney can evaluate your PSSD claim at no cost.
PSSD has been documented following discontinuation of numerous SSRIs and SNRIs including Zoloft, Paxil, Prozac, Lexapro, Celexa, Effexor, and Cymbalta. Both drug classes appear in regulatory documents and medical literature describing post-discontinuation sexual dysfunction. A connected attorney can assess whether the specific antidepressant you took supports a PSSD lawsuit. Start with a free evaluation.
PSSD claim values depend on severity and duration of symptoms, documented impact on quality of life and relationships, how long you were unaware that symptoms could be drug-related, and what evidence exists of the manufacturer's prior knowledge. Because PSSD litigation is still building toward consolidated proceedings, individual values are not yet benchmarked by mass settlements. A connected attorney can give you a realistic assessment during a free, confidential review.
Yes. The FDA required manufacturers to update SSRI and SNRI prescribing information to disclose the risk of persistent sexual dysfunction after stopping the drug. The European Medicines Agency issued similar requirements. These mandated updates are central to PSSD litigation — they demonstrate the risk was recognized at the highest regulatory levels and that prior product labeling was insufficient. Find out if the labeling gap applies to your claim.
Yes. Statutes of limitation for PSSD lawsuits vary by state — typically two to three years — but the discovery rule may apply, meaning the clock starts when you first connected your symptoms to your prior antidepressant use rather than when you first stopped taking it. Filing sooner is strongly advisable as courts establish timelines. Contact a connected attorney today to confirm your deadline.
They Knew It Could Last Forever.
They Said Nothing.
The evaluation is free. The consultation is confidential. There is no obligation until you choose to move forward.